Abstract: The present invention is related to novel compositions comprising at least one active ingredient of the family of the triazines combined with another active ingredient and specific compounds that allow the reduction of foam formation. More particularly, the invention relates to compositions in the form of aqueous suspensions comprising a triazine, an iron complex, and one or more surfactant(s) having a particular HLB.

Abstract: The invention relates to improved methods for protecting non-human animals with triazine compounds by intramuscular or subcutaneous injection(s). The invention can be used with various triazines, such as toltrazuril, in different non-human animals, such as a porcine, an ovine, a bovine, a canine, a feline, or an avian, for protecting them against infectious diseases, such as protozoan disorders.

Abstract: The invention relates to methods of making compounds useful for production of paclitaxel and analogs or derivatives thereof.

Abstract: According to some embodiments, a method and an apparatus are provided to display a webpage comprising a fundraising interface and a selection of interactive games and educational programs, receive an indication of an interaction of a user with at least one of the interactive games and educational programs, and provide rewards associated with the user's interaction with the at least one of the interactive games and educational programs.

Abstract: A glycopeptide composition with improved antibiotic activity is disclosed, along with a method of preparing such a composition and a pharmaceutical composition made therefrom.

Abstract: The BC powders (particle size<10 ?m, Taiwan Paiho) are activated with surfactant sodium alginate under stirred for 1 h. The as-prepared BC powders (2 g) are immersed into 100 mL of biamminesilver nitrate ([Ag(NH3)2]NO3) solutions, which are formed by adding 28 wt. % aqueous ammonia into AgNO3 solution at room temperature. After stirring for 1 h, dilute aqueous solutions of hydrazine monohydrate are separately prepared and introduced to the BC-AgNO3 solutions in appropriate quantities (molar ratio 1:1 with respect to silver nitrate) by a syringe. Stirring is continued under inert atmosphere at room temperature for another 4 h. The BC/Ag particles are separated and washed with deionized water and ethanol, then dried in vacuum at 60° C. for overnight.

Abstract: The present invention relates to molecules that stabilize and/or enhance CD154 activity, compositions comprising these molecules, methods for using these molecules and compositions (e.g., pharmaceutical compositions) comprising them. Specifically, the molecules can be used for enhancing immune function (e.g., enhancing Th1 cytokine expression), stimulating immune responses, and/or treating certain disorders (e.g., cancer, infectious disease, and immune compromised states). The invention also relates to kits and compositions comprising the molecules.

Abstract: A method and system for constructing a test using a computer system that performs specification matching during the test creation process is disclosed. A test developer determines one or more test item databases from which to select test items. The test item databases are organized based on psychometric and/or content specifications. The developer can examine the textual passages, artwork or statistical information pertaining to a test item before selecting it by clicking on a designation of the test item in a database. The developer can then add the test item to a list of test items for the test. The test development system updates pre-designated psychometric and content specification information as the developer adds each test item to the test. The test developer can use the specification information to determine whether to add to, subtract from, or modify the list of test items selected for the test.

Abstract: Process for producing a hydrochloride of a vancomycin antibiotic, comprising subjecting an aqueous solution of a hydrochloride of a vancomycin antibiotic to a primary freezing at from −1° C. to −20° C. for a time sufficient to grow ice crystals, to form a primarily frozen substance, then subjecting said primarily frozen substance to a secondary freezing at from −25° C. to −80° C. to form a completely frozen solid, and then drying the resulting frozen solid in vacuo; and product obtained by the process.

Abstract: A vibrating screed for processing a floor layer, more particularly a so-called vibrating beam, of the type including a vibrating board (2), a vibrating mechanism (3) cooperating with the vibrating board, and a handle (4) whereby the vibrating mechanism comprises an eccentric (7) seated in bearings (5-6) and a motor (8) for driving the eccentric, wherein the bearings and the eccentric are fixed in a split body by means of a clamping mechanism on the split body.

Abstract: A method for treating or preventing mastitis in mammals is disclosed. The method contemplates the intramammary injection or dipping the teat with micrococcin antibiotics, preferably micrococcin P1 or P2, which do not interfere with the production of cheese and yoghurt using milk from treated animals. Hydrophobic antibiotics such as micrococcin P1 or P2 can be administered prior to infection to effectively suppress the rate, severity, and duration of subsequent bacterial infection, or can be administered subsequent to infection to effectively treat mastitis.

Abstract: Novel antibiotic stalobacins H-1 and I-1 having physico-chemical properties as shown in Table 4 are provided, which are excellent antibiotics showing marked effects on Gram-positive bacteria.

Abstract: Antibiotics 10381v, w, x, y, z1, z2, pre-b and t are antibiotics producible by culturing the microorganism Streptomyces arginensis in an aqueous medium and isolation thereof. The structure of Antibiotic 10381y is given below as formula IV. These antibiotics inhibit the growth of selected species of bacteria and may also be useful as a growth promotant in animals.

Abstract: The present invention concerns new antiobiotic substances demoninated de-acyl antibiotics A40926, de-acyl antibiotic A 40926P and antibiotic A 40926 amino glucronyl aglycon, and the use of these substances in the treatment of infectious diseases involving microorganisms susceptible to it.

Abstract: The present invention relates to a novel polypeptide having the following presumed structure: ##STR1## and the compound has both excellent fungicidal and protozoicidal effects.

Abstract: The invention is directed toward the use of amphotericin B and derivatives thereof as inhibitors of serine-proteases and for applying these inhibitors for the production of medicinal products intended for the treatment of infection by the human immunodeficiency virus (HIV).

Abstract: A novel antibiotic complex designated BU-4224V produced by fermentation of Kibdelosporangium albatum sp. nov. Strain R761-7. The complex may be separated chromatographically into bioactive components designated BU-4224V A, B.sub.1, B.sub.2, and C. The components BU-4224V B.sub.1 and B.sub.2 display both antiviral and antimicrobial activity, while component BU-4224V A has antimicrobial activity and component BU-4224V C has antiviral activity.

Abstract: The present invention relates to a novel polypeptide having the following presumed structure: ##STR1## and the compound has both excellent fungicidal and protozoicidal effects.

Abstract: A system for reporting groupings of answers to test questions. The system receives in electronic form answers to test questions, after which the system divides the answers according to predefined categories and organizes the divided answers into separate groupings. The system reports the answers in the groupings. The system can also merge a test answer with other report information to provide an indication of a process used in obtaining a given answer.

Abstract: A degenerative disease selected from the group consisting of cystic fibrosis, chronic bronchitis and bronchiectasia is treated by administering to a subject a therapeutically effective amount of WS7622A mono-or disulfate or pharmaceutically acceptable salt thereof.

Abstract: WS7622A mono- or di-sulfate and pharmaceutically acceptable salts thereof. WS7622A exhibits human leukocyte elastase-inhibiting activity.

Abstract: A novel antibiotic complex designated BU-4224V produced by fermentation of Kibdelosporangium albatum sp. nov. Strain R761-7. The complex may be separated chromatographically into bioactive components designated BU-4224V A, B.sub.1, B.sub.2, and C. The components BU-4224V B.sub.1 and B.sub.2 display both antiviral and antimicrobial activity, while component BU-4224V A has antimicrobial activity and component BU-4224V C has antiviral activity.

Abstract: A novel antibiotic complex, A59770, individual factors and derivatives thereof, are provided. The A59770 compounds are useful as pesticides, particularly as rodenticides. Further provided are methods for reducing a rodent population, rodenticidal compositions, and an A59770-producing Amycolatopsis orientalis culture.

Abstract: Newly-discovered antibiotic A10255 factors B, C, E, F, G, H, and J are produced by submerged aerobic fermentation of Streptomyces gardneri NRRL 15537 and NRRL 18260 or an A10255-producing variant or mutant thereof. The antibiotics are active against a wide variety of pathogenic bacteria, and also enhance feed-utilization efficiency in chickens, weanling pigs, cattle and sheep. The antibiotics can also be used to detect the thiostrepton-resistance gene in Streptomyces species.

Abstract: New glycopeptide antibiotic A80407, comprising A80407A and A80407B, is produced by Kibdelosporangium philippinensis strains NRRL 18198, and NRRL 18199 or A80407-producing mutants of these strains. The A80407 antibiotics have excellent activity against Gram-positive bacteria, increase feed-utilization efficiency in monogastric and ruminant animals and improve weight gains in animals.

Abstract: New glycopeptide antibiotics MM 49728, MM 55266, MM 55267/1, MM 55267/2 and MM 55268 are produced by fermentation of Amycolatopsis sp. NCIB 40089.

Abstract: A mixture of new coumamidine compounds are produced by a microorganism, belonging to the genus Saccharopolyspora. The compounds have antibiotic activity against a broad spectrum of bacteria.

Abstract: A method of treating pulmonary emphysema or adult respiratory distress syndrome in a subject in need thereof which comprises administering to the subject an effective amount of WS7622A, B, C and/or D, derivatives thereof, or their pharmaceutically acceptable salt.

Abstract: Two related, novel antibiotic substances, peptifluorin and neopeptifluorin, are prepared by cultivation of strains of Pseudomonas fluorescens, A. T. C. C. No. 53,958 and A. T. C. C. No. 55,129, respectively.

Abstract: Compounds comprising a linear .beta.1.fwdarw.6 glucan esterified by caproic acid, the number of D-glucose residues being from 7 to 40 and the number of caproic acid residues being from 2 to 30, may be be obtained by fermentation of a microorganism of the genus Aureobasidium. These compounds are designated HS-142-1. Preferred microorganism is Aureobasidium pullulans var. melanigenum KAC-2383 (FERM-BP 2407).The compounds of the present invention exhibit excellent antagonistic activity to ANP and are capable of inhibiting the bonding of ANP to ANP receptors.

Abstract: The present invention relates to new WS7622A, B, C and/or D substances, derivatives thereof and pharmaceutical compositions containing the new substances as active ingredients.

Abstract: Novel compounds, called chloropolysporins B and C, and salts thereof have antibiotic properties and would appear to be members of the class of glycopeptide antibiotics containing chlorine. They may be produced by cultivating a suitable strain of microorganism of the genus Micropolyspora, especially Micropolyspora sp. SANK 60983 (FERM BP-538). They may be combined with conventional pharmaceutically acceptable carriers or diluents for therapeutic use or incorporated into edible excipients, such as feed or water, for use as a growth-promoting agent, especially for farm animals.

Abstract: A novel compound, DC-107, is produced by culturing a microorganism belonging to the genus Streptomyces. It is useful as a medicine because of its antibacterial and anti-tumor activity.

Abstract: New peptide antibiotic A54145, individual A54145 components A, A.sub.1, B, B.sub.1, C, D, E and F and their pharmaceutically acceptable salts, are useful antibacterial agents which also improve growth performance in animals, especially poultry. Biologically pure cultures of the A54145-producing Streptomyces fradiae cultures NRRL 18158, NRRL 18159 and NRRL 18160 cultures and methods of making antibiotic A54145 using those cultures are also provided.

Abstract: AB-006 Antibiotics and their AB-006 and AB-006b Antibiotic components, obtained by controlled aerobic culture of Streptomyces s.p. NCIB 12425, in an aqueous nutrient culture is disclosed. The AB-006 Antibiotics show biological activity, and in particular fungicidal and insecticidal activity.

Abstract: A method for enhancing the transdermal flux of a transdermally deliverable drug through intact skin is described in which the drug is delivered simultaneously with sucrose monolaurate or a mixture of sucrose esters of coconut fatty acids, which is predominantly sucrose monolaurate. Preferred embodiments of therapeutic systems for delivering the drug and the sucrose ester employ a matrix containing drug at a concentration above saturation.

Abstract: The present invention concerns a new antibiotic substance arbitrarily denominated antibiotic A 40926 complex and its factors antibiotic A 40926 factor A, antibiotic A 40926 factor B, antibiotic A 40926 factor B.sub.0, antibiotic A 40926 factor PA and antibiotic A 40926 factor PB, a process for producing them by culturing the new strain Actinomadura sp. ATCC 39727 or an A 40926 producing variant or mutant thereof and the use of these new antibiotic substances in the treatment of infectious diseases involving microorganisms susceptible to them. The antibiotic substances of the invention are glycopeptidic substances belonging to the vancomycin class of antibiotics which have binding capacity to Acyl-D-Alanyl-D-Alanine.

Abstract: Novel compounds, called chloropolysporins B and C, and salts thereof have antibiotic properties and would appear to be members of the class of glycopeptide antibiotics containing chlorine. They may be produced by cultivating a suitable strain of miroorganism of the genus Micropolyspora, especially Micropolyspora sp. SANK 60983 (FERM BP-538). They may be combined with conventional pharmaceutically acceptable carriers or diluents for therapeutic use or incorporated into edible excipients, such as feed or water, for use as a growth-promoting agent, especially for farm animals.

Abstract: A unique four-solvent system comprising methanol, dimethylformamide, methylene chloride and water is employed to provide an improved process for the purification and crystallization of amphotericin B.

Abstract: Gel-free concentrated aqueous formulations of vancomycin hydrochloride are provided which comprise the antibiotic salt at a concentration between about 12% and about 50% w/v and a gel-inhibiting compound, e.g., ethanol, at a concentration between about 1% and about 20% v/v. The gel-free formulations are especially useful in a freeze-drying process for preparing vancomycin hydrochloride as a dry flowable powder in bulk or in unit-dosage form.

Abstract: The present invention concerns new antibiotic substances denominated antibiotic A 40926 N-acylaminoglucuronyl aglycon complex AB, antibiotic A 40926 N-acylaminoglucuronyl aglycon factor A, antibiotic A 40926 N-acylaminoglucuronyl aglycon factor B, antibiotic A 40926 N-acylaminoglucuronyl aglycon factor B.sub.0, antibiotic A 40926 N-acylaminoglucuronyl aglycon factor B.sub.1, antibiotic A 40926 aglycon and the addition salts thereof, a process for their preparation starting from antibiotic A 40926 complex or a factor thereof, and their use in the treatment of infectious diseases involving microorganisms susceptible to them.

Abstract: Cultivation of a strain of the microorganism Micromonospora sp. A.T.C.C. No. 53481, yields the novel antibiotic substance glyphomicin, which is a mixture of glyphomicin A and glyphomicin B.

Abstract: A novel antibiotic, A 42867, is prepared by cultivating the strain Nocardia sp. ATCC 53492, or an antibiotic A 42867-producing mutant or variant thereof, under submerged aerobic conditions in the presence of assimilable sources of carbon, nitrogen and inorganic salts. The antibiotic and its addition salts are useful in the treatment of infectious diseases and as growth promotant agents.

Abstract: A novel antibiotic complex of "vancomycin-like" antibiotics, AAD 216 complex, is produced by the cultivation of a fermentation broth containing Kibdelosporangium aridum Shearer gen. nov., sp. nov. ATCC 39323 microorganisms in an aqueous nutrient medium under submerged aerobic conditions. The AAD 216 complex and its major bioactive components; AAD 216A, AAD 216B, and AAD 216C exhibit antibiotic activity and growth promotant activity.

Abstract: Antibiotic 82-85-8A, or a pharmacologically acceptable non-toxic salt thereof, having the following physicochemical properties:(1) Elementary analysis: C.sub.31 H.sub.47 N.sub.8 O.sub.10 Cl (determined by high resolution mass spectrometry)(2) Molecular weight: 726.5 (determined by field desorption mass spectrometry and calculated from elementary analysis)(3) Melting point: 162.degree.-167.degree. C. (partially immersed at 160.degree. C., completely melted at 167.degree. C., no browning)(4) Specific rotation: [.alpha.].sub.D.sup.20 =-56.degree. (c=0.24, methanol)(5) Ultraviolet absorption spectrum (in methanol): shown in FIG. 1(6) Infrared absorption spectrum (KBr): shown in FIG. 2(7) Solubility:soluble: chloroform, dichloromethane, ethyl acetate, methanol, ethanol,slightly soluble: acetone,insoluble: hexane, water;(8) Color reaction:Positive: iodine, sulfuric acid, Dragendorf reactionNegative: ninhydrin, ferric chloride(9) Nature: weakly basic substance.

Abstract: A purified isolate of an actinomycete identified as ATCC 39366 is capable of producing the antimicrobial compound CL-1957D.The antimicrobial compound CL-1957D is produced by cultivating isolate ATCC 39366 under aerobic conditions in a culture medium containing assimilable sources of carbon and nitrogen until a substantial quantity of the CL-1957D compound is produced, and subsequently isolating the CL-1957D compound.The antibiotic compound CL-1957D and pharmaceutical compositions comprising this substance together with a pharmaceutically acceptable carrier is also disclosed, as are methods of treating microbial infections in mammals, employing these pharmaceutical compositions.

Abstract: A hitherto undescribed microorganism, Streptomyces virginiae NRRL 12525, which upon culturing produces the A41030 antibiotic complex comprising several factors. The A41030 antibiotics produced show antibacterial activity against the gram-positive genera Staphylococcus and Streptococcus which are resistant to penicillin. In addition, these antibiotic act to promote growth and improve feed efficiency in ruminant animals, poultry and swine, and other livestock, and to improve milk production in ruminant animals.

Abstract: A novel subspecies of Kibdelosporangium aridum, subsp. largum (SK&F-AAD-609) produces AAD-216 antibiotics and AAD-609 antibiotics, the ADD-609 antibiotics differing from the AAD-216 antibiotics in presence of glucosamine in the glycolipid radical in place of amino glucuronic acid.

Abstract: A electrochemical cell has a generally cylindrical battery stack comprised of disc-shaped components including atlernating first polarity electrodes and second polarity electrodes. Pairs of first polarity electrodes are coupled by ring-shaped couling members. The coupling members include radial channels such as grooves which allow the passage of a liquid cell component from a central well into the battery stack.

Abstract: The invention relates to a new compound, designated FR-68504. The compound has antitimor activities and is effective in the treatment of various tumors in both human beings and animals.There is also provided a process for preparing FR-68504 compound which comprises culturing a FR-68504 producing strain belonging to the genus Amauroascus in a nutrient medium.Pharmaceutical composition comprising FR-68504 as an active ingredient is also described.